{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-052231","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.789169+00:00","generated_at":"2026-05-14T23:27:12.049417+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio secures long-term umbilical cord supply for CORDStrom MSC platform via Anthony Nolan agreement","bullets":["AN granted exclusive license to use donor materials; INmune Bio added as party with joint liability for royalty payments.","AN receives 2% royalty on net sales of each product, capped at £5M annually; £400+VAT fees per cord tissue, CPI-adjusted annually.","Term runs until 10 years after first commercial sale; either party may terminate with 30 days (IMB/INMB) or 6 months (AN) notice.","Pipeline targets RDEB, CORDStrom-col7a, CORDStrom-TRAIL (oncology), osteoarthritis, and systemic lupus erythematosus (SLE).","Materials handled per GMP and HTA standards; enables global regulatory compliance (FDA, EMA, MHRA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052231","json":"https://secwatch.observer/filing/0001213900-26-052231.json","markdown":"https://secwatch.observer/filing/0001213900-26-052231.md","text":"https://secwatch.observer/filing/0001213900-26-052231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/ea0288685-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:27:12.049417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b21b6256b459eb05833691031c73ed5ed00b3b4","claim":"Inmune Bio, Inc. entered into Amended and Restated Material Transfer and License Agreement with Anthony Nolan valued at an annual cap of £5,000,000 (effective 2026-04-29).","evidence_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}},{"accession":"0001683168-26-004424","ticker":"LTRX","company_name":"LANTRONIX INC","filed_at":"2026-06-01T20:15:28+00:00","headline":"Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004424","json":"https://secwatch.observer/filing/0001683168-26-004424.json","markdown":"https://secwatch.observer/filing/0001683168-26-004424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/lantronix_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm"}},{"accession":"0001493152-26-022133","ticker":"BNAI","company_name":"Brand Engagement Network Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"BEN invests $1M in Accelevate, signs exclusive Mexico reseller and global deal","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022133","json":"https://secwatch.observer/filing/0001493152-26-022133.json","markdown":"https://secwatch.observer/filing/0001493152-26-022133.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 7, 2026, following the successful completion of due diligence, entered into two definitive Reseller Agreements (the “Commercial Agreements”) with Accelevate.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm"}},{"accession":"0001193125-26-214698","ticker":"PBT","company_name":"PERMIAN BASIN ROYALTY TRUST","filed_at":"2026-05-08T23:59:59+00:00","headline":"Court approves trust indenture amendments eliminating 75% supermajority requirement","event_type":"other_material","sec_items":["1.01","3.03","5.03","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214698","json":"https://secwatch.observer/filing/0001193125-26-214698.json","markdown":"https://secwatch.observer/filing/0001193125-26-214698.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/0001193125-26-214698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/2026-05_pbt_rslt_of_hear.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"Argent Trust Company, the trustee of the Trust, entered into Amendment No. 2 to the Amended and Restated Trust Indenture of Permian Basin Royalty Trust dated May 8, 2026 (the “Amendment”) implementing the modifications approved by the Court.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/0001193125-26-214698-index.htm"}},{"accession":"0001213900-26-053475","ticker":null,"company_name":"MEDICAL EXERCISE INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Medical Exercise signs first franchise agreement for Canadian OnCore Longevity Center","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053475","json":"https://secwatch.observer/filing/0001213900-26-053475.json","markdown":"https://secwatch.observer/filing/0001213900-26-053475.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/ea0289708-8k_medical.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm"}},{"accession":"0001213900-26-054034","ticker":null,"company_name":"MEDICAL EXERCISE INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Medical Exercise signs first OnCore franchise in Regina, Canada; exits back pain market","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054034","json":"https://secwatch.observer/filing/0001213900-26-054034.json","markdown":"https://secwatch.observer/filing/0001213900-26-054034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/0001213900-26-054034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/ea0289883-8ka1_medical.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/0001213900-26-054034-index.htm"}},{"accession":"0001683168-26-003551","ticker":"DPLS","company_name":"DarkPulse, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"DarkPulse secures exclusive U.S. Navy license for 3 LADAR patents","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003551","json":"https://secwatch.observer/filing/0001683168-26-003551.json","markdown":"https://secwatch.observer/filing/0001683168-26-003551.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/0001683168-26-003551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/darkpulse_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm","comparable_excerpt":"On May 7, 2026, DarkPulse, Inc., a Delaware corporation (the “ Company ”), entered into an Exclusive Patent License Agreement (Agreement No. NLICENSE-NAWCWDCL-26-027) (the “ License Agreement ”) with the United States of America, as represented by the Secretary of the Navy, acting through the Naval Air Warfare Center Weapons Division (“ NAWCWD ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/0001683168-26-003551-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}